Replies to post #774399 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Trial was nebulous and it cost a fortune in stingy UK. Embarrassing questions would be ask why they let it drag on for so many years so best just to pass it around until investors / advocates move on/forget, is my guess.

[JTORENCE]

So we sit and wait once again while patients suffer and die everyday and families pray for a miracle that the fuckin MHRA has held up for bullshit reasons. Gonna be at least to 2026 before the ECA issue gets resolved.
A fuckin crime against humanity.

[dennisdave]

well the MHRA would not just hold up the decision until the guideline arrives, to then just say: super now that the guideline has been made available to the public we can finally, after over 18 months of review, decline the DCVAXL application right. There would not be a small percentage of logic in that. So if you agree that ECA issue is the holdup, and you thus no longer think that NWBO is appealing objections, which is huge coming from you, then the next logical step is to follow my reasoning.

[dstock07734]

There are no issues at all. You are conjuring up issues.

Have you figured out DCVax-L is the same as ATL-DC? In case you still have confusion, let me repeat there is only one company on this planet that can pulse DCs with tumor lysate and make them present hundreds of tumor-associated peptides to immune system.

That's why the following two trials sponsored NCI most likely adopted the same pulsing technology.
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
https://clinicaltrials.gov/study/NCT00923351

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
https://clinicaltrials.gov/study/NCT03035331

BTW, have you read George Zavoico's resume? You don't happen to think you have better judgement on $NWBO than him, do you?

George Zavoico, PhD
Northwest Biotherapeutics
Dr. Zavoico earned his BS in Biology from St. Lawrence University in Canton, NY, and a Ph.D. in Physiology from the University of Virginia, Charlottesville, VA. He completed post-doctoral fellowships in Pharmacology at the University of Connecticut Health Center in Farmington, CT, and Hematology at Brigham & Women’s Hospital and Harvard Medical School, Boston, MA. At Bristol-Myers Squibb, Dr. Zavoico was involved in drug discovery research in thrombosis and then cell therapy and complement therapeutics development at Alexion Pharmaceuticals and T Cell Sciences. For several years, Dr. Zavoico served as a consultant in competitive intelligence, regulatory affairs, and medical writing for the biotech and pharmaceutical industries, which included Pfizer and Boehringer-Ingelheim as clients. He then transitioned to become a sell-side equity analyst for Cantor-Fitzgerald, MLV & Co., JonesTrading, and B. Riley FBR. In over 15 years he covered a broad range of small-to-mid size biotech and biopharmaceutical companies engaged in developing drugs and/or cell therapies for cancer, autoimmune diseases and inflammation, neurological and cardiovascular disorders, rare diseases, and vaccines. In the past several years, Dr. Zavoico returned to work in the biotech industry in investor relations and corporate development to first assist Cue Biopharma and now Northwest Biotherapeutics in developing their cancer immunotherapies. Dr.Zavoico has authored more than 30 scientific papers and book chapters and was the recipient of a Financial Times/Starmine Analyst award for two years in a row. He has collaborated with the NY Academy of Sciences for over 30 years in planning and organizing symposia on multiple topics, including the annual Frontiers of Cancer Immunotherapy symposium.